Fundraising FoxORI Capital
Venture capitalHong Kong · Seed–Series A · 15 people tracked
Find your way into ORI Capital
Sign up to see every warm intro you have to ORI Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ORI Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
ORI Capital backs early-stage biotech companies worldwide, concentrating on diagnostics, drug delivery, and therapeutics. Its focus is on disease areas with the highest mortality rates, specifically cancer, cardiovascular, and neurodegenerative diseases. The firm combines scientific expertise with a mission-driven approach to investing in companies aimed at saving lives, applying both artificial and human intelligence to its investment process.
Source: firm website, verified Sep 27, 2026.
Team · 15 people
from the firm's website & public directories
What they invest in
from 3 of 6 portfolio companiesBiotech ×3Healthtech ×2Medical Devices ×2Deep Tech ×1
HQs:United States×2United Kingdom×1
Investments · 6 tracked
founders shown can be your intro path
CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.
BiotechHealthtechMedical Devices
Arthur Kuan(Chairman and Chief Executive Officer)in
Co-investorsDecheng CapitalForesite CapitalLongitude CapitalPalm Drive CapitalRA CapitalTCG Crossover+3 more
Natick, US
Gang Song(Executive Officer, Director)Moonsoo Jin(Executive Officer, Director)Hong Fang Song(Director)
Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy.
BiotechDeep TechHealthtechMedical DevicesLondon, GB
Donald Kohn(Scientific Founder)Adrian Thrasher(Scientific Founder)Frank E. Thomas(Executive Officer)inSteven M. Altschuler(Director)John Curnutte(Director)
BoardBobby Gaspar(Scientific Founder)in
Co-investorsAlbionVCF-Prime CapitalForesite CapitalUCL Technology Fund4BIO CapitalAgent Capital+3 more
Cambridge, MA biotech developing stem cell-derived islet therapy plus an immune-protective device for type 1 diabetes; acquired by Vertex for $950M.
BiotechCambridge, US
Robert Millman(Executive Officer, Director)
BoardTodd Foley(Executive Officer, Director)inMitch Finer(Director)Stephen Knight(Director)inJim Scopa(Director)William Sahlman(Director)
Co-investorsARCH Venture PartnersF-Prime CapitalJDRF T1D FundSlater Technology Fund6 Dimensions CapitalCowen Healthcare Investments+4 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
<UNKNOWN>
Exits · 2
1 IPOs · 1 acquisitionsCG OncologyNASDAQ: CGONSemma Therapeuticsacq. by Vertex Pharmaceuticals
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| CG Oncology | 4.8% | $28.00 | Dec 2024 | $100.5M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has ORI Capital made?
- ORI Capital has 6 tracked investments, 2 of which have exited.
- What stage does ORI Capital invest at?
- ORI Capital invests at the Seed, Series A stages.
- What sectors does ORI Capital focus on?
- ORI Capital focuses on AI & Machine Learning, Biotech, Healthtech, Impact & Social Good, Longevity, Medical Devices.
- Where is ORI Capital located?
- ORI Capital is headquartered in Hong Kong, HK.
- Who does ORI Capital co-invest with?
- ORI Capital most often shares deals with ARCH Venture Partners, F-Prime Capital, JDRF T1D Fund, among 4 tracked co-investors.
Similar investors
Future Positive Capital is a venture firm backing entrepreneurs building companies that address large-scale global challenges across health, sustainability and technology.
Selvedge Venture is an impact-focused investor backing founders and startups working to reduce the healthcare burden of age-related medical conditions, investing at pre-seed, seed and Series A stages.
LIFTT is a venture capital holding company focused on deep tech technologies, using an operational, multi-vertical approach aimed at generating impact. It works to transform scientific research into high-impact companies, accelerating the path from lab to market.
CABHI (Centre for Aging + Brain Health Innovation) is a pan-Canadian organization that funds and supports researchers, innovators, and startups working on brain health and aging solutions, and helps healthcare and community organizations adopt them.
Northern Gritstone is an independent investment firm backing science and technology startups in the North of England, focused on university spinouts and early-stage deep tech and life sciences companies from the Leeds, Manchester, Sheffield and Liverpool region.